Evidence map›Paper›PMID 42881060›Full record

ArticleJournal of advanced research2026

Corrigendum to "Longitudinal prediction of drug response in high-grade serous ovarian cancer organoid cultures aligning with clinical responses" [J. Adv. Res. 83 (2026) 379-390].

Enrico Cavarzerani, Isabella Caligiuri, Michele Bartoletti, Giuseppe Corona, Tiziana Perin, Antonio Palumbo, Antonino Ditto, Tommaso Occhiali, Vincenzo Canzonieri, Flavio Rizzolio

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Enrico CavarzeraniDepartment of Molecular Sciences and Nanosystems, Ca' Foscari University of Venice, Venezia, 30172, Italy.
Isabella CaligiuriPathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, 33081, Italy.
Michele BartolettiUnit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, 33081, Italy.
Giuseppe CoronaImmunopathology and Cancer Biomarkers, CRO Aviano, National Cancer Institute, IRCCS, Aviano, 33081, Italy.
Tiziana PerinPathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, 33081, Italy.
Antonio PalumboPathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, 33081, Italy.
Antonino DittoGynecologic Oncology Unit, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy.
Tommaso OcchialiGynecologic Oncology Unit, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy.
Vincenzo CanzonieriPathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, 33081, Italy; Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, 34127, Italy. Electronic address: vcanzonieri@cro.it.
Flavio RizzolioDepartment of Molecular Sciences and Nanosystems, Ca' Foscari University of Venice, Venezia, 30172, Italy; Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, 33081, Italy. Electronic address: flavio.rizzolio@unive.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42881060

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.